BioSpace News Archive

Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, will hold its 2020 Annual Meeting of Stockholders in a virtual meeting format on Wednesday, June 3, 2020 at 10:00 a.m. (Eastern Time) at www.viewproxy.com/AnnovisBio/2020/VM . Shareholders of record that attend the Annual Meeting will be able to vote and submit ques

Freitag will continue as member of board of directors and serve as special counsel in transitional role through October

Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has closed on a credit facility of up to $50 million from funds managed by Marathon Asset Management, a global credit solutions partner. Proceeds from the facility will generally be used to support the commercial launch of ANJESO TM (meloxicam) injection, and for working capital purposes. JMP Securities LLC acted as

Novel wireless device designed to optimize shunt management in patients with hydrocephalus [01-June-2020] EVANSTON, Ill. , June 1, 2020 /PRNewswire/ -- Rhaeos, Inc. (Rhaeos), a private medical technology company focused on addressing a clinical unmet need in the care of patients with hydrocephalus, today announced its initial product, FlowSense™, a wireless, noninva

Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced the Portuguese Medicine Regulatory Authority has granted approval for reimbursement of TEGSEDI® for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis.

Regeneron and Intellia to co-develop potential hemophilia A and B treatments using their jointly-owned targeted transgene insertion capabilities

New BRILINTA indication expands treatment to high-risk coronary patients without a history of stroke or heart attack

Calliditas Therapeutics AB will launch an investor roadshow for a contemplated initial public offering of American Depositary Shares in the United States for trading on The Nasdaq Global Market in the United States and a concurrent private placement of common shares to certain qualified investors in Europe and other countries outside of the United States.

Alkahest Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, announced the initiation of a clinical study to explore the use of an extracorporeal medical device to remove excess Beta-2 microglobulin from circulation for the treatment of cognitive impairment in patients undergoing hemodialysis for end stage renal disease.

Biomerica also announces its first Japanese patent has been granted for its InFoods® IBS Diagnostic Guided Therapy technology